1. Discovery of a Potent Antiosteoporotic Drug Molecular Scaffold Derived from Angelica sinensisand Its Bioinspired Total Synthesis
- Author
-
Zou, Jian, Qiu, Zuo-Cheng, Yu, Qiang-Qiang, Wu, Jia-Ming, Wang, Yong-Heng, Shi, Ke-Da, Li, Yi-Fang, He, Rong-Rong, Qin, Ling, Yao, Xin-Sheng, Wang, Xin-Luan, and Gao, Hao
- Abstract
Angelica sinensis, commonly known as Dong Quai in Europe and America and as Dang-gui in China, is a medicinal plant widely utilized for the prevention and treatment of osteoporosis. In this study, we report the discovery of a new category of phthalide from Angelica sinensis, namely falcarinphthalides A and B (1and 2), which contains two fragments, (3R,8S)-falcarindiol (3) and (Z)-ligustilide (4). Falcarinphthalides A and B (1and 2) represent two unprecedented carbon skeletons of phthalide in natural products, and their antiosteoporotic activities were evaluated. The structures of 1and 2, including their absolute configurations, were established using extensive analysis of NMR spectra, chemical derivatization, and ECD/VCD calculations. Based on LC-HR-ESI-MS analysis and DFT calculations, a production mechanism for 1and 2involving enzyme-catalyzed Diels−Alder/retro-Diels−Alder reactions was proposed. Falcarinphthalide A (1), the most promising lead compound, exhibits potent in vitro antiosteoporotic activity by inhibiting NF-κB and c-Fos signaling-mediated osteoclastogenesis. Moreover, the bioinspired gram-scale total synthesis of 1, guided by intensive DFT study, has paved the way for further biological investigation. The discovery and gram-scale total synthesis of falcarinphthalide A (1) provide a compelling lead compound and a novel molecular scaffold for treating osteoporosis and other metabolic bone diseases.
- Published
- 2024
- Full Text
- View/download PDF